维生素E对CAPD患者氧化应激和微炎症状态的影响及对血管内皮功能的保护作用
|
摘要
目的
研究口服抗氧化剂维生素E对持续非卧床腹膜透析(CAPD)患者氧化应激及微炎症状态的影响,以及对CAPD患者血管内皮功能的改善作用。
方法
选择2008年7月至2009年6月在北京大学第三附属医院肾内科透析中心透析时间超过3个月的CAPD患者50例,治疗组34例口服维生素E 400 mg/d,未治疗组16例未口服维生素E,选择15名健康者作对照组。服药6周后,观察用药前后血浆中维生素E及血浆丙二醛(MDA)、循环晚期氧化蛋白产物(AOPP)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)等氧化应激指标以及血浆C-反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等炎症指标的变化。另外选择血流介导的血管舒张功能(FMD)做为血管内皮功能指标,研究抗氧化治疗对血管内皮功能的保护作用。
结果
口服维生素E 400 mg/d治疗六周后,治疗组患者MDA、AOPP较治疗前明显降低(P<0.05),维生素E、SOD活性、GSH-PX活性较治疗前升高(P<0.05),炎症指标CRP和TNF-α较治疗前明显降低(P<0.05),血管内皮功能较治疗前有改善,FMD较前明显升高(P<0.05),IL-6水平较治疗前有所降低,但治疗前后差异无统计学意义(P>0.05)。
结论
口服维生素E(400 mg/d)可以改善CAPD患者的氧化应激状态；并且可以部分抑制患者的微炎症状态；改善血管内皮功能。短期应用大剂量维生素E未见明显副反应。
Objective:
To investigate the influence of Vitamin E on the oxidative stress, micro-inflammation and the effects of vitamin E on improving vascular endothelial function in patients with CAPD(continuous ambulatory peritoneal dialysis) and the safety of Vitamin E supplementation in these patients.
Method:
Fifty patients with CAPD and fifteen healthy volunteers were involved in this study. Thirty-four patients were administered 400mg/d of Vitamin E for 6 weeks. Sixteen patients were not administered Vitamin E. The levels of vitamin E (Vit E),malondialdehyde (MDA),advanced oxidation protein product (AOPP) superoxide dismutase(SOD),activity of glutathione peroxidase (GSH-PX) microinflammation cytokines C-reactive protein (CRP),interleukin-6(IL-6) interleukin-10(IL-10) and tumor necrosis factor(TNF-α) in plasma were measured at the beginning and the end of administering Vit E. The levels of flow mediated dilatation (FMD) were measured simultaneously to learn the protection of antioxidant treatment to endothelial function.
Results:
400mg/d of Vit E supplementation of six weeks decrease the levels of plasma MDA, AOPP, CRP, TNF-a(P<0.05),while the level of Vit E, SOD, GSH-PX, FMD were increased (P<0.05).The plasma levels of IL-6 were reduced but there were no significant change.(p>0.05).
Conclusion:
There are oxidative stress and microinflammation state in patients with CAPD. 400 mg/d of VitE ameliorates oxidative stress and micro-inflammation state and vascular endothelial function without apparent side effect, although farther observation are needed.
研究口服抗氧化剂维生素E对持续非卧床腹膜透析(CAPD)患者氧化应激及微炎症状态的影响,以及对CAPD患者血管内皮功能的改善作用。
方法
选择2008年7月至2009年6月在北京大学第三附属医院肾内科透析中心透析时间超过3个月的CAPD患者50例,治疗组34例口服维生素E 400 mg/d,未治疗组16例未口服维生素E,选择15名健康者作对照组。服药6周后,观察用药前后血浆中维生素E及血浆丙二醛(MDA)、循环晚期氧化蛋白产物(AOPP)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)等氧化应激指标以及血浆C-反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等炎症指标的变化。另外选择血流介导的血管舒张功能(FMD)做为血管内皮功能指标,研究抗氧化治疗对血管内皮功能的保护作用。
结果
口服维生素E 400 mg/d治疗六周后,治疗组患者MDA、AOPP较治疗前明显降低(P<0.05),维生素E、SOD活性、GSH-PX活性较治疗前升高(P<0.05),炎症指标CRP和TNF-α较治疗前明显降低(P<0.05),血管内皮功能较治疗前有改善,FMD较前明显升高(P<0.05),IL-6水平较治疗前有所降低,但治疗前后差异无统计学意义(P>0.05)。
结论
口服维生素E(400 mg/d)可以改善CAPD患者的氧化应激状态；并且可以部分抑制患者的微炎症状态；改善血管内皮功能。短期应用大剂量维生素E未见明显副反应。
Objective:
To investigate the influence of Vitamin E on the oxidative stress, micro-inflammation and the effects of vitamin E on improving vascular endothelial function in patients with CAPD(continuous ambulatory peritoneal dialysis) and the safety of Vitamin E supplementation in these patients.
Method:
Fifty patients with CAPD and fifteen healthy volunteers were involved in this study. Thirty-four patients were administered 400mg/d of Vitamin E for 6 weeks. Sixteen patients were not administered Vitamin E. The levels of vitamin E (Vit E),malondialdehyde (MDA),advanced oxidation protein product (AOPP) superoxide dismutase(SOD),activity of glutathione peroxidase (GSH-PX) microinflammation cytokines C-reactive protein (CRP),interleukin-6(IL-6) interleukin-10(IL-10) and tumor necrosis factor(TNF-α) in plasma were measured at the beginning and the end of administering Vit E. The levels of flow mediated dilatation (FMD) were measured simultaneously to learn the protection of antioxidant treatment to endothelial function.
Results:
400mg/d of Vit E supplementation of six weeks decrease the levels of plasma MDA, AOPP, CRP, TNF-a(P<0.05),while the level of Vit E, SOD, GSH-PX, FMD were increased (P<0.05).The plasma levels of IL-6 were reduced but there were no significant change.(p>0.05).
Conclusion:
There are oxidative stress and microinflammation state in patients with CAPD. 400 mg/d of VitE ameliorates oxidative stress and micro-inflammation state and vascular endothelial function without apparent side effect, although farther observation are needed.
引文
[1]Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study[J]. J Am Soc Nephrol. 2002;13(7):1918-1927
[2]Allan J, Collins MD, Bertram Kasiske MD, et al. Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States[J]. Am J Kidney Dis, 2005,45(1):A5-A7
[3]Geoffrey S Teehan, Daqing Guo, Mary C Perianayagam, et al. Reprocessed (High-Flux) Polyflux Dialyzers Resist Trans-Membrane Endotoxin Passage and Attenuate Inflammatory Marker[J]. Blood Purif, 2004, 22(4): 329-337.
[4]王剑青,邓安国,戴勇.维持性血液透析患者微炎症状态相关因子的变化[J].临床内科杂志,2005,22(7):451-454.
[5]王彩丽,魏枫,史平,等.慢性炎症反应对慢性肾功能衰竭患者并发症的影响[J].放射免疫学杂志,2006,19(1):18-21.
[6]高志军,刘子栋.慢性肾衰竭血液透析与腹膜透析患者微炎症反应的比较及相关因素分析[J].中国血液净化,2005,4(4):205-210.
[7]管红斌,桓文穆,吕路,等.腹膜透析患者c一反应蛋白水平与贫血及营养不良的关系[J].广东药学院学报,2005,21(6):739-742.
[8]叶云洁,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系[J].中华肾脏病杂志,2004,20(3):173-176.
[9]Kaysen GA. The microinflammatory state in uremia:.causes and potential consequences[J]. J Am Soc Nephrol. 2001,12(7):1549-1557.
[10]Descamps-Latscha B, Driieke T, Witko-Sarsat V, et al. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy[J]. Semin Dial.2001 14(3):193-199
[11]Himmelfarb J, Stenvinkel P, Dcizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremiafJ]. Kidney Int. 2002, 62(5):1524-1538.
[12]Busch M, Franke S, Moller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein[J]. Kidney Int. 2004, 66(1):338-347.
[13]Terrier N, Senecal L, Dupuy AM, et al. Association between novel indices of malnutrition-inflammation complex syndrome and cardiovascular disease in hemodialysis patients[J]. Hemodial Int. 2005, 9(2): 159-168.
[14]Ohkuma T, Minagawa T, Takada N, et al. C-reactive protein, lipoprotein(a), homocysteine,and male sex contribute to carotid atherosclerosis in peritoneal dialvsis patients[J]. Am J Kidney Dis.2003,42(2):355-361
[15]Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women[J]. N Engl J Med. 1993, 328(20): 1444-1449.
[16]Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. N Engl J Med. 1993,328(20): 1450-1456.
[17]Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease .in endstage renal disease (SPACE): randomized placebo controlled trial[J]. Lancet. 2000, 356(9237): 1213-1218.
[18]Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) [J].Lancet. 1996,347(9004):781-6.
[19]陈缓,周玫,侯凡凡,等.氧化应激与慢性肾功能衰竭透析患者动脉粥样硬化的发生[J].中华肾脏病杂志,2002,18(5):377-381
[20]Dasgupta A, Hussain S , Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis[J]. Nephron, 1992, 60(1) :56-59
[21]Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Mail-lard reaction prod- ucts in skin collagen in diabetes and aging[J]. J Clin Invest, 1993, 91 (6): 2463 -2469.
[22]Miyata T, Fu MX, Kurokawa K, et al. Autoxidation products of both carbohyd- rates and lipids are increased in uremic plasma : Is there oxidative stress in uremia[J]? Kidney Int, 1998, 54(4):1290-1295.
[23]Weiss MF , Erhard P, Kader - Attia FA ,et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease[J]. Kidney Int, 2000,57(6): 2571 - 2585.
[24]Peng KF, Wu XF, Zhao HW, et al. Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells[J].Chin Med X(Engl),2006,119(13): 1088-1093.
[25]Fortuno A,Beloqui O,San Jose G, et al .Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease[J].Kidney Int, 2005,68(99): S71-75.
[26]Oberg BP, McMenamin E,Lucas FL,et al.Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease[J]. Kidney Int,2004, 65(3): 1009-10016.
[27]Mcgrath L T , Douglas AF , McClean E , et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular HD[J]. Clin Chim Acta,1995,235(2): 179 -188.
[28]Hassan MQ , Hussain SA , Zaki MA , et al. Prospective effects of antioxidants against uraemia- induced lipid peroxidation and glutathione depletion in humans[J]. Pharmocol Toxicol, 1995,77(6): 407 - 411.
[29]Richard MJ ,Arnaud J ,Jurkovitz C , et al. Trace elements lipid peroxidation abnormalities in patients with chronic renal failure[J]. Nephron, 1991,57(1):10-15.
[30]Miyata T ,Wada Y, Cai Z ,et al. Implication of an increase oxidative stress in the formation of advanced glycation end products in patients with end - stage renal failure[J]. Kidney Int,1997,51(4): 1170-1181.
[31]Wratten ML , Tetta C , Ursini F , et at. Oxidant stress in hemodialysis : Prevention and treatment strategies[J]. Kidney Int, 2000 , 58 (76) :126 - 132.
[32]Wratten ML, Sereni L, Tetta C. Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins[J]. Artif Organs, 2000,24(9): 685 - 690.
[33]Stenvinkel P,Heimburger O,Paultre F,et al.Strong association between malnutrition, inflammation,and atherosclerosis in chronic renal failure[J]. Kidney Int, 1999, 55(5):1899-1911
[34]Sienvinkel PHolmberg I,Heimburger O,Diczfalusy U.A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure:Evidence of incressed oxidative stress in malnourished patients[J]. Nephrol Dial Transplant, 1998,13(10): 2594-2600
[35]Schomig M ,Eisenhandt A ,Ritz E. The microinflammatory state of uremia[J]. Blood Purif,2000,18(4): 327-332.
[36]卞红磊，魏艳静．黄芪配伍丹参对活动期溃疡性结肠炎患者血清超氧化物歧化酶和丙二醛的影响[J]．时珍国医国药,2007,18(7)：1699-1700
[37]吴瑗，赵汉宁，刘仿．终末期肾病患者的微炎症和氧化应激水平的变化[J]．现代医药卫生，2008，24(12)：1757-1758
[38]陈香美，张冬．应重视维持性血液透析患者微炎症状态的认识[J]．中国血液净化,2005，4(2):59-61.
[39]Bergstrom J, Lindholm B, Lacson E, et aLWhat are the cause and consequences of the chronic inflammatory state in chronic dialysis patients[J]. Seminars in Dialysis, 2000,13:163-175.
[40]Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients[J]:.Kidney Int, 1998, 54(1): 236-244.
[41]Kalender B, Ozdemir A.C, Dervisoglu E, et al. Quality of life in chronic kidney disease: effects of treatment modality, depression, malnutrition and inflammation[J]. International Journal of Clinical Practice,2007, 61(4):569-576.
[42]Vera Krane, Christiane Drechsler, Christoph Wanner. Dyslipidemia, inflammation and dialysis outcomes: what we know now[J]. Dialysis and transplantation, 2006, 15(6):566-570.
[43]Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients[J]. Am J Kidney Dis,1997, 30(6): 923 - 927.
[44]Foley R,Parfrey PS,Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal disease[J].Am J Kidney Dis,1998, 32: s112-s119
[45]Jan GOxidative strees in chronic renal failure [J]. Nephrol Dial Transplant,2001,16(9): 2135-2141
[46]Pupim LB,Himmelfarb J,Mcmonagle E,et al.Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. [J].Kidney InL 2004,65 (8):2371-2379
[47] Kaysen GA.C-reactive protein:a story half told[J]. Semin Dial,2000,13(4): 143-146
[48] Maggi E,Bellazzi R,Falaschi F,et aLAutoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis[J]. Kidney Int, 1994,45(7): 876-883
[49] Verma S.Wang CH,Li SH.et al.A self-fulfilling prophecy:C-reactive protein attenustes nitric oxide production and inhibits angiogenesis[J]. Circulation, 2002,106: 913-919
[50] Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102(8): 1000-1006
[51] Cermak J, Key NS, Bach RR, et a l.C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor[J]. Blood, 1993, 82(8): 513-520.
[52] Daniel T. Peptide growth factors and kidney, in the kidney:physiology and pathophysiologyfM]. New York: Seldin DW and Giebisch, 1992: 3135
[53] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilatation in haman veins in vivo[J]. Circulation, 1997,96(9): 3042-3047.
[54] Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway [J]. Circulation, 2000,102(21):2636-2642
[55] Azzi A, BosGoboinik D, Hensey C. The protein kinase C family[J]. Eur JBiochem, 1992,208 (3): 547-557.
[56] Nava M, Quiroz Y, Vaziri ND, et al. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rat[J].Am J Physiol Renal Physiol,2003,284: F447-454
[57] Rodry Guez-Iturbe B,Zhan CD,Qufroz Y,et a 1 .Antioxidant-fish diet improves hypertension and reduce renal immune infiltration in spontaneously hypertensive rat[J]. Hypertension,2003,41:341-346
[58] Yoshikawa T, Yoshida N. Vitamin E and leukocyte-endothelial cell interactions [J].Antioxid Redox Signal, 2000,2 (4) : 821-825.
[59] Himmelfarb J,Kane J,McMonagle E,et al.Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease[J]. Kidney hit, 2003, 64: 978-99
[60] Thomas SR, tocker R. Molecular action of vitamin E in lipoprotein oxidation:implication for atherosclemsis[J]. Free Radic Biol Med, 2000, 28(12): 1795-1805.
[61] 冯利平，张玲，钟玲，等.口服维生素E对维持性血液透析患者血清几种炎症因子水平的影响[J].第三军医大学学报.2007.29(8):733-735.
[62] Omata M, Higuchi C, Demura R, et al. Reduction of neutrophil activation by vitamin E modified dialyzer membranes [J]. Nephron, 2000, 85(3): 221-231.
[63] Lonn E, Yusuf S, Dzavik V, et al. Effect of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) [J]. Circulation, 2001,103(7):919-925
[64]Yukawa S, Mune M, Otani H. Vitamin E disturbances in chronic renal failure[J]. Nippon Rinsho, 1999,57(10): 2366-2370
[65]Galzava P, Amici G, Calconi G, et al .Reduction of echinocytes post-haemodialysis [J]. Nephrol Dial Transplant, 1995,10 (5): 716-721.
[66]Canaud B, Cristol J-P, morena M, et al. Imbalance of oxidants and antioxidants in heamodialysispatients[J]. Blood Purif, 1999, 17 (2-3): 99-106.
[67]Cristol JP, Bosc JY, Badiou S, et al. Erythropoietin and oxidative stress in haemodialysis: benefical effects of vitamin E supplemention[J]. Nephrol Dial Transplant, 1997, 12 (11):2312-2317.
[68]Miyazaki H,Matsuoka H,Itabe H,et al.Hemodialysis impairs endothelial function via oxidative stress: Effect of vitamin E-coated dialyzer[J].Circulation,2000,101(9): 1002-1006
[1]Shimig M, Eisenhandt A, Ritz E. The micro infammatory state of uremia[J].Blood Purif, 2000,18(4):327-332
[2]Geoffrey S Teehan, Daqing Guo, Mary C Perianayagam, et al. Reprocessed (High-Flux) Polyflux Dialyzers Resist Trans-Membrane Endotoxin Passage and Attenuate Inflammatory Marker[J].Blood Purif,2004,22(4):329-337.
[3]叶云洁,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系[J].中华肾脏病杂志,2004,20(3)：173-176.
[4]Kaysen GA. The microinflammatory state in uremia:causes and potential consequences[J]. J Am Soc Nephrol.2001,12(7):1549-57.
[5]Descamps-Latscha B, Drueke T, Witko-Sarsat V.Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy[J].Semin Dial,2001,14(3):193-199
[6]Bergstrom J, Lindholm. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients[J]? Seminars in Dialysis,2000,13(8):164-166
[7]JMC,Cross CE.Free radicals,antioxidants,and human disease:where are we now[J]? J Lab Clin med,1992,119:598-620.
[8]王迪浔,金惠铭.人体病理生理学[M].北京：北京人民卫生出版社,2002,515-516
[9]Witko-Sarsat V,Friedlander M, Capeillere-Blandin C, et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia[J].Kidney Int,1996,49(7): 1304-1313.
[10]Witko-Sarsat V,Friedlander M,Nguyen Khoa T, et al,Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure[J].J Immunol,1998,161:2524-2532.
[11]Ward RA,Brier ME.Retrospective analyses of large medical databases:what do they tell us[J]?J Am Soc Nephrol,1999,10(2):429-432
[12]Koenig JS,Fischer M,Bulant E, et al.Antioxidant status in patients on chronic hemodialysis therapy:impact of parenteral selenium supplementation[J].Wien Klin Wochenschr,1997,109(1):13-19
[13]Himmelfarb J, Stenvinkel P, Ikizler TA, et al.The elephant in uremia:oxidant stress as a unifying concept of cardiovascular disease in uremia[J].Kidney Int,2002,62(5): 1524-1538
[14]Descamps-Latscha B,Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure[J].Kidney Int,2001,59(78):S108-113.
[15]Capeillere-Blandin C,Gausson V, Descamps-Latscha B, et al.Biochemical and spectrophoto-metric significance of advanced oxidized protein products[J].Biochim Biophys Acta,2004,1689:91-102.
[16]Woods AA, Linton SM, Davies MJ. Detection of HOCL mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques[J].Biochem J,2003, 370(2):729-735.
[17]Peuchant E,Carbonneau MA.Dubourg L,et al. Lipoperoxidation in plasma and red blood cells of patients undergoing hemodialysis:Vitamin A,E and iron status[J].Free Radic Biol Med,1994,16(3):339-346.
[18]Miyata T, Taneda S,Kawai R, et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin forming amyloid fibrils in patients with dialysis-related amyloidosis[J].Proc Nalt Acad Sci USA,1996,93(6):2353-2358.
[19]Mcgrath LT, Douglas AF, McClean E, et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular HD[J].Clin Chim Acta,1995,235(2):179-188.
[20]Hassan MQ, Hussain SA, Zaki MA, et al.Prospective effects of antioxidants against uraemia-induced lipid peroxidation and glutathione depletion in humans[J].Pharmocol Toxicol,1995,77(6):407-411.
[21]Grone HJ, Grone EF, Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis[J].Lab Invest,2002,82(1): 5-14.
[22]Capeillere-Blandin C, Gausson V, Nguyen AT, et al.Respective role of uraemic toxins and myeloperoxidase in the uraemic state[J].Nephrol Dial Transplant,2006,21(6):1555-1563.
[23]Kalousova M, Zima T, Tesar Vet, et al. Advanced glycation end products and advanced Oxidation protein products in hemodialyzed patients[J].Blood Purify,2002,20(6): 531-536.
[24]Yuan F, Liu SX, Tian JW.Advanced oxidation protein products induce reactive oxygen species production in endothelial cells[J].Di Yi Jun Yi Da Xue Bao,2004,24(12): 1350-1352.
[25]Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Mail-lard reaction products in skin collagen in diabetes and aging[J].J Clin Invest,1993,91(6):2463-2469.
[26]Miyata T, Fu MX, Kurokawa K, et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma:Is there oxidative stress in uremia[J]?Kidney Int, 1998,54(4):1290-1295.
[27]Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease[J].Kidney Int,2000,57(6):2571-2585.
[28]Miyata T, Charles Van Ypersele de Strihou, Kurokawa K, et al. Alterations in non-enzymatic biochemistry in uremia:Origin and significance of "carbonyl stress"in long-term uremic complications [J].Kidney Int,1999,55:389-399.
[29]Miyata T, Ueda Y, Shizato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure:Renal implications in the pathophysiology of pentosidine[J].J Am Soc Nephrol,1996,7:1198- 1206.
[30]Miyata T, Ueda Y, Yoshida A, et al. Clearance of pentosidine, an advanced glycation end product,by different modalities of renal replacement therapy[J].Kidney Int,1997,51:880-887.
[31]Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure [J].Kidney Int, 1997,51(4):1170-1181.
[32]侯凡凡,张训,王斌会,等.Nε-羧甲基赖氨酸时慢性血液透析病人晚期糖基化终产物的天然结构[J].中华内科杂志,1998,37(10)：663-666.
[33]Fu M X,Requena J R,Jenkins AJ,et al. The advanced glycation end-product,Nε-(carboxymethyl) lysine (CML),is a product of both lipid peroxidation and glycation reactions[J].J Biol Chem,1996,271:9982-9986.
[34]Jan Galle.Oxidative stress in chronic renal failure[J].Nephrol Dial Transplant 2001,16: 2135-2137.
[35]Magus A, Mihkel z. Bengt E Endothelium-dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int.2003, (84):50-53.
[36]Diaz-Buxo JA,Gotloib L.Agents that modulate peritoneal mem-brane structure and function[J].Petit Dial Int,2007,27(1):16-30.
[37]Honda K,Nitta K,Horita S,et al.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure[J].Nephron,1996,72(2):171-176.
[38]Keshaviah P. Adequancy of peritoneal dialysis. In:Gokal R,Nolph KD.The texbook of peritoneal dialysis[M].Dordrecht:kluwer Academic publishers,1994:419-422.
[39]Herrera J,Nava M,Romero F,et al.Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis,2001 Apr:37(4):750-7
[40]Eiselt J,Racek J,Opatrny K Jr.Oxidative stress:the effect of erythropoietin and the dialysis membrane[J].Int J Artif Organs,2000,23(1):33-40
[41]Pawlaczyk K, Oko A, Lindholm B, et al.Malnutrition-inflammation-atherosclerosis (MIA syndrome) in patients with renal failure[J].Pol Merkuriusz Lek,2003,15(88):334-341.
[42]Decamps-Latscha B,Witko-Sarsat V, Nguyen-Khoa T, et al.Early prediction of IgA nephropathy progression:proteinuria and AOPP are strong prognostic makers[J].Kidney Int,2004,66(4):1606-161.
[43]Hou FF,Ma ZG,Mei CL,et al.Epidemiology of cardiovascular risk in Chinese chronic kidney disease patients[J].Chung-Hua I HSUCH Tsa Chih,2005,85(11):753-9.
[44]Robert N, Foley,Anne M, Murray, et al.Chronic Kidney Disease and the Risk for Cardiovascular Disease,Renal Replacement,and Death in the United States Medicare Population 1998 to 1999[J].J Am Soc Nephrol,2005,16(2):489-495.
[45]Alan S.Go,Glenn M.Chertow,Dongjie Fan,et al.Chronic Kidney Disease and the Risks of Death,Cardiovascular Events,and Hospitalization[J].N Engl J Med,2004,351(13): 1296-1305.
[46]Selmeci L,Antal M,et al.Advanced oxidation protein products(AOPP)for monitoring oxidative stress in critically ill patients:a simple,fast and inexpensive automated technique[J].Clin Chem Lab Med,2005,43(3):294-297.
[47]Stenvinkel P, Heimburger O, Paultre F, et al.Strong association between malnutritions inflammation,and atherosclerosis in chronic renal failure [J].Kidney Int,1999,55(5): 1899-1911
[48]Michael GS, Linda FF, Casey Crump, et al.Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency[J].Circulation,2003,107(1): 87-92
[49]齐志宏.C-反应蛋白与动脉粥样硬化的关系.北京医学,2005,27(4)：246-248.
[50]Kato A,Odamaik M,Taki,ta M,et al.C-reactive protein is a predictor of short-term mortality in hemodialysis patients[J].Am J Nephrol,2001,21(2):176-178
[51]Yeun JY, Levine RA, Mantadilok V, et al.C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis Patients[J].Am J Kidney Dis,2000,35(3): 469-476
[52]Cooper AC, Mikhail A, Lethbridge MW, et al.Increased expression of erythropoiesis inhibiting cytokines(IFN-7,TNF-a,IL-10 andlL-13)by T cells in patients exhibiting a poor response to erythropoietin therapy[J].J Am Soc Nephrol,2003,14(5):1776-1784.
[53]Pereira BJ, Shapiro L, King A J, et al.Plasma levels of IL-I beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure,CAPD and hemodialysis patients[J]. Kidney Int,1994,45(3):890-896
[54]Ortega O,Rodriquez I,Gallar P,et al.A.Significance of high C-reactive protein levels in pre-dialysis patients[J].Nephrol Dial Transplant,2002,17(6):1105-1109
[55]Boenisch O,EhmkeK D,Heddergott A,et al.C-reactive-protein and cytokine plasma levels in hemodialysis patients[J].J Nephrol,2002,5(5):547-551
[56]Raj DS, Lim G, Levi Metal.Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy[J].Am J Kidney Dis,2004,43(1):154-160
[57]Descamps Latscha B,Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis[J].Nephrologie,2003,24(7):377-379.
[58]Haubitz M, Brunkhorst R, Wrenger E, et al.Chronic induction of C-reactive protein by hemodialysis but not peritoneal dialysis therapy[J].Protein Dial Int.1996,16(2):158-162.
[59]Schindler R, Boenisch O, Fischer C, et al.Effects of hemodialysis membrane on the inflammatory reaction in vivo[J].Clin Nephrol.2000,53(6):452-459.
[60]Verthelyi D,Ishii KJ,Gursel M,et al.Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs[J].J Immunol,2001,166(4):2372-2377
[61]Elwakkad AS.Mohamed SI.Fathalla M.Relation between hypercholesterolemia and vascular endothelial microinflammation[J].Eastern Mediterranean Health Journal.2007, 13(3):191-199.
[62]Fichtlscherer S,Rosenberger G,Walter DH, et al.Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J].Circulation, 2000,102(9):1000-1006
[63]Verma S,Wang CH,Li SH,et al.A self-fulfilling prophecy:C-reactive protein attenustes nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106(8):913-919
[64]Cermak J, key NS, Bach RR, et al.C-reactive protein induces human peripheral blood monocytes to synthesize trssue factor[J].Blood,1993,82(2):513-520
[65]Libby P,Aikawa M.Stabilization of atherosclerotic plaques:new mechanisms and clinical targets[J].Nature Med,2002,8(11):1257-1262
[66]Stompor T, Pasowicz M, Sulowicz W,et al.An association between coronary artery calcificatronscore, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritioneal dialysis[J].Am J Kidney Dis,2003,41(1):203-211
[67]Kalantar-Zadeh K, McAllister CJ,Lehn RS,et al.Effect of malnutrition-Inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients[J]. Am J Kidney Dis,2003,42(4):761-773
[68]Tintut Y,Patel J,Parhami F,et al.Tumor necrosis factor-a promotes in vitro calcification of vascular cell via the cAMP pathway[J].Circulation,2000,102(5):2636-2842
[69]Baranyp, Divinho-Filho JC, Bergstrom J. Hight C-reactive protein in a strong predictor of resistance to erythropoietin in hemodialysis patients[J].Am J Kidney Dis,1997,29(3): 565-568
[70]Alleu DA,Breen C,Yaqoob MM,et al.Inhibition of CFU-E colony formation in nremic patients with inflammatory disease:role of 1FN-gamma and TNF-alpha[J].Investigative Med,1999,47(5):204-211
[71]Bovy C,Tsobo C,Crapanzano L, et al.Factors determining the percentage of hypochromic red blood cells in hemodialysis patients[J]. Kidney Int,1999,56(5):1113-1119
[72]Stenvinkel P, Heimburger O, Lindholm B,et al.Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition,inflammation and atherosclerosis(MIA)syndrome[J].Nephrol Dial Transplant,2000,15(7):953-960
[73]Hodkova M, Dusilova-Sulkova S,Skalicka A, et al.Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients[J].Ren Fail,2005,27(2):135-141
[74]Mune M, Yukawa S,Kishino M, et al.Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients[J].Kidney Int Suppl,1999,71:S126-129
[75]Tepel M, Van der Giet M, Statz M, et al.The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure:a randomized, controlled trial[J].Circulation,2003,107(7):992-995.
[76]Sezer MT, Katirci S, Demir M. Short-term effect of simvastain treatment on inflammatory parameters in peritoneal dialysis patients[J].Scandinavian journal of Urology & Nephrology, 2007,41(5):436-441.
[77]Kumar S,Raftery M, Yaqoob M, et al.Anti-inflammatory effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors(statins)in peritoneal dialysis patients[J]. Peritoneal Dialysis International,2007,27(3):283-287.
[78]何甲均,王煜伦,郑莘.ACEI与ATl受体拮抗剂合用治疗轻中度慢性肾衰高血压临床观察[J].天津医药,2004,32(2)：272--273
[2]Allan J, Collins MD, Bertram Kasiske MD, et al. Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States[J]. Am J Kidney Dis, 2005,45(1):A5-A7
[3]Geoffrey S Teehan, Daqing Guo, Mary C Perianayagam, et al. Reprocessed (High-Flux) Polyflux Dialyzers Resist Trans-Membrane Endotoxin Passage and Attenuate Inflammatory Marker[J]. Blood Purif, 2004, 22(4): 329-337.
[4]王剑青,邓安国,戴勇.维持性血液透析患者微炎症状态相关因子的变化[J].临床内科杂志,2005,22(7):451-454.
[5]王彩丽,魏枫,史平,等.慢性炎症反应对慢性肾功能衰竭患者并发症的影响[J].放射免疫学杂志,2006,19(1):18-21.
[6]高志军,刘子栋.慢性肾衰竭血液透析与腹膜透析患者微炎症反应的比较及相关因素分析[J].中国血液净化,2005,4(4):205-210.
[7]管红斌,桓文穆,吕路,等.腹膜透析患者c一反应蛋白水平与贫血及营养不良的关系[J].广东药学院学报,2005,21(6):739-742.
[8]叶云洁,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系[J].中华肾脏病杂志,2004,20(3):173-176.
[9]Kaysen GA. The microinflammatory state in uremia:.causes and potential consequences[J]. J Am Soc Nephrol. 2001,12(7):1549-1557.
[10]Descamps-Latscha B, Driieke T, Witko-Sarsat V, et al. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy[J]. Semin Dial.2001 14(3):193-199
[11]Himmelfarb J, Stenvinkel P, Dcizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremiafJ]. Kidney Int. 2002, 62(5):1524-1538.
[12]Busch M, Franke S, Moller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein[J]. Kidney Int. 2004, 66(1):338-347.
[13]Terrier N, Senecal L, Dupuy AM, et al. Association between novel indices of malnutrition-inflammation complex syndrome and cardiovascular disease in hemodialysis patients[J]. Hemodial Int. 2005, 9(2): 159-168.
[14]Ohkuma T, Minagawa T, Takada N, et al. C-reactive protein, lipoprotein(a), homocysteine,and male sex contribute to carotid atherosclerosis in peritoneal dialvsis patients[J]. Am J Kidney Dis.2003,42(2):355-361
[15]Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women[J]. N Engl J Med. 1993, 328(20): 1444-1449.
[16]Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. N Engl J Med. 1993,328(20): 1450-1456.
[17]Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease .in endstage renal disease (SPACE): randomized placebo controlled trial[J]. Lancet. 2000, 356(9237): 1213-1218.
[18]Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) [J].Lancet. 1996,347(9004):781-6.
[19]陈缓,周玫,侯凡凡,等.氧化应激与慢性肾功能衰竭透析患者动脉粥样硬化的发生[J].中华肾脏病杂志,2002,18(5):377-381
[20]Dasgupta A, Hussain S , Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis[J]. Nephron, 1992, 60(1) :56-59
[21]Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Mail-lard reaction prod- ucts in skin collagen in diabetes and aging[J]. J Clin Invest, 1993, 91 (6): 2463 -2469.
[22]Miyata T, Fu MX, Kurokawa K, et al. Autoxidation products of both carbohyd- rates and lipids are increased in uremic plasma : Is there oxidative stress in uremia[J]? Kidney Int, 1998, 54(4):1290-1295.
[23]Weiss MF , Erhard P, Kader - Attia FA ,et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease[J]. Kidney Int, 2000,57(6): 2571 - 2585.
[24]Peng KF, Wu XF, Zhao HW, et al. Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells[J].Chin Med X(Engl),2006,119(13): 1088-1093.
[25]Fortuno A,Beloqui O,San Jose G, et al .Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease[J].Kidney Int, 2005,68(99): S71-75.
[26]Oberg BP, McMenamin E,Lucas FL,et al.Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease[J]. Kidney Int,2004, 65(3): 1009-10016.
[27]Mcgrath L T , Douglas AF , McClean E , et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular HD[J]. Clin Chim Acta,1995,235(2): 179 -188.
[28]Hassan MQ , Hussain SA , Zaki MA , et al. Prospective effects of antioxidants against uraemia- induced lipid peroxidation and glutathione depletion in humans[J]. Pharmocol Toxicol, 1995,77(6): 407 - 411.
[29]Richard MJ ,Arnaud J ,Jurkovitz C , et al. Trace elements lipid peroxidation abnormalities in patients with chronic renal failure[J]. Nephron, 1991,57(1):10-15.
[30]Miyata T ,Wada Y, Cai Z ,et al. Implication of an increase oxidative stress in the formation of advanced glycation end products in patients with end - stage renal failure[J]. Kidney Int,1997,51(4): 1170-1181.
[31]Wratten ML , Tetta C , Ursini F , et at. Oxidant stress in hemodialysis : Prevention and treatment strategies[J]. Kidney Int, 2000 , 58 (76) :126 - 132.
[32]Wratten ML, Sereni L, Tetta C. Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins[J]. Artif Organs, 2000,24(9): 685 - 690.
[33]Stenvinkel P,Heimburger O,Paultre F,et al.Strong association between malnutrition, inflammation,and atherosclerosis in chronic renal failure[J]. Kidney Int, 1999, 55(5):1899-1911
[34]Sienvinkel PHolmberg I,Heimburger O,Diczfalusy U.A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure:Evidence of incressed oxidative stress in malnourished patients[J]. Nephrol Dial Transplant, 1998,13(10): 2594-2600
[35]Schomig M ,Eisenhandt A ,Ritz E. The microinflammatory state of uremia[J]. Blood Purif,2000,18(4): 327-332.
[36]卞红磊，魏艳静．黄芪配伍丹参对活动期溃疡性结肠炎患者血清超氧化物歧化酶和丙二醛的影响[J]．时珍国医国药,2007,18(7)：1699-1700
[37]吴瑗，赵汉宁，刘仿．终末期肾病患者的微炎症和氧化应激水平的变化[J]．现代医药卫生，2008，24(12)：1757-1758
[38]陈香美，张冬．应重视维持性血液透析患者微炎症状态的认识[J]．中国血液净化,2005，4(2):59-61.
[39]Bergstrom J, Lindholm B, Lacson E, et aLWhat are the cause and consequences of the chronic inflammatory state in chronic dialysis patients[J]. Seminars in Dialysis, 2000,13:163-175.
[40]Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients[J]:.Kidney Int, 1998, 54(1): 236-244.
[41]Kalender B, Ozdemir A.C, Dervisoglu E, et al. Quality of life in chronic kidney disease: effects of treatment modality, depression, malnutrition and inflammation[J]. International Journal of Clinical Practice,2007, 61(4):569-576.
[42]Vera Krane, Christiane Drechsler, Christoph Wanner. Dyslipidemia, inflammation and dialysis outcomes: what we know now[J]. Dialysis and transplantation, 2006, 15(6):566-570.
[43]Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients[J]. Am J Kidney Dis,1997, 30(6): 923 - 927.
[44]Foley R,Parfrey PS,Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal disease[J].Am J Kidney Dis,1998, 32: s112-s119
[45]Jan GOxidative strees in chronic renal failure [J]. Nephrol Dial Transplant,2001,16(9): 2135-2141
[46]Pupim LB,Himmelfarb J,Mcmonagle E,et al.Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. [J].Kidney InL 2004,65 (8):2371-2379
[47] Kaysen GA.C-reactive protein:a story half told[J]. Semin Dial,2000,13(4): 143-146
[48] Maggi E,Bellazzi R,Falaschi F,et aLAutoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis[J]. Kidney Int, 1994,45(7): 876-883
[49] Verma S.Wang CH,Li SH.et al.A self-fulfilling prophecy:C-reactive protein attenustes nitric oxide production and inhibits angiogenesis[J]. Circulation, 2002,106: 913-919
[50] Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102(8): 1000-1006
[51] Cermak J, Key NS, Bach RR, et a l.C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor[J]. Blood, 1993, 82(8): 513-520.
[52] Daniel T. Peptide growth factors and kidney, in the kidney:physiology and pathophysiologyfM]. New York: Seldin DW and Giebisch, 1992: 3135
[53] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilatation in haman veins in vivo[J]. Circulation, 1997,96(9): 3042-3047.
[54] Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway [J]. Circulation, 2000,102(21):2636-2642
[55] Azzi A, BosGoboinik D, Hensey C. The protein kinase C family[J]. Eur JBiochem, 1992,208 (3): 547-557.
[56] Nava M, Quiroz Y, Vaziri ND, et al. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rat[J].Am J Physiol Renal Physiol,2003,284: F447-454
[57] Rodry Guez-Iturbe B,Zhan CD,Qufroz Y,et a 1 .Antioxidant-fish diet improves hypertension and reduce renal immune infiltration in spontaneously hypertensive rat[J]. Hypertension,2003,41:341-346
[58] Yoshikawa T, Yoshida N. Vitamin E and leukocyte-endothelial cell interactions [J].Antioxid Redox Signal, 2000,2 (4) : 821-825.
[59] Himmelfarb J,Kane J,McMonagle E,et al.Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease[J]. Kidney hit, 2003, 64: 978-99
[60] Thomas SR, tocker R. Molecular action of vitamin E in lipoprotein oxidation:implication for atherosclemsis[J]. Free Radic Biol Med, 2000, 28(12): 1795-1805.
[61] 冯利平，张玲，钟玲，等.口服维生素E对维持性血液透析患者血清几种炎症因子水平的影响[J].第三军医大学学报.2007.29(8):733-735.
[62] Omata M, Higuchi C, Demura R, et al. Reduction of neutrophil activation by vitamin E modified dialyzer membranes [J]. Nephron, 2000, 85(3): 221-231.
[63] Lonn E, Yusuf S, Dzavik V, et al. Effect of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) [J]. Circulation, 2001,103(7):919-925
[64]Yukawa S, Mune M, Otani H. Vitamin E disturbances in chronic renal failure[J]. Nippon Rinsho, 1999,57(10): 2366-2370
[65]Galzava P, Amici G, Calconi G, et al .Reduction of echinocytes post-haemodialysis [J]. Nephrol Dial Transplant, 1995,10 (5): 716-721.
[66]Canaud B, Cristol J-P, morena M, et al. Imbalance of oxidants and antioxidants in heamodialysispatients[J]. Blood Purif, 1999, 17 (2-3): 99-106.
[67]Cristol JP, Bosc JY, Badiou S, et al. Erythropoietin and oxidative stress in haemodialysis: benefical effects of vitamin E supplemention[J]. Nephrol Dial Transplant, 1997, 12 (11):2312-2317.
[68]Miyazaki H,Matsuoka H,Itabe H,et al.Hemodialysis impairs endothelial function via oxidative stress: Effect of vitamin E-coated dialyzer[J].Circulation,2000,101(9): 1002-1006
[1]Shimig M, Eisenhandt A, Ritz E. The micro infammatory state of uremia[J].Blood Purif, 2000,18(4):327-332
[2]Geoffrey S Teehan, Daqing Guo, Mary C Perianayagam, et al. Reprocessed (High-Flux) Polyflux Dialyzers Resist Trans-Membrane Endotoxin Passage and Attenuate Inflammatory Marker[J].Blood Purif,2004,22(4):329-337.
[3]叶云洁,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系[J].中华肾脏病杂志,2004,20(3)：173-176.
[4]Kaysen GA. The microinflammatory state in uremia:causes and potential consequences[J]. J Am Soc Nephrol.2001,12(7):1549-57.
[5]Descamps-Latscha B, Drueke T, Witko-Sarsat V.Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy[J].Semin Dial,2001,14(3):193-199
[6]Bergstrom J, Lindholm. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients[J]? Seminars in Dialysis,2000,13(8):164-166
[7]JMC,Cross CE.Free radicals,antioxidants,and human disease:where are we now[J]? J Lab Clin med,1992,119:598-620.
[8]王迪浔,金惠铭.人体病理生理学[M].北京：北京人民卫生出版社,2002,515-516
[9]Witko-Sarsat V,Friedlander M, Capeillere-Blandin C, et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia[J].Kidney Int,1996,49(7): 1304-1313.
[10]Witko-Sarsat V,Friedlander M,Nguyen Khoa T, et al,Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure[J].J Immunol,1998,161:2524-2532.
[11]Ward RA,Brier ME.Retrospective analyses of large medical databases:what do they tell us[J]?J Am Soc Nephrol,1999,10(2):429-432
[12]Koenig JS,Fischer M,Bulant E, et al.Antioxidant status in patients on chronic hemodialysis therapy:impact of parenteral selenium supplementation[J].Wien Klin Wochenschr,1997,109(1):13-19
[13]Himmelfarb J, Stenvinkel P, Ikizler TA, et al.The elephant in uremia:oxidant stress as a unifying concept of cardiovascular disease in uremia[J].Kidney Int,2002,62(5): 1524-1538
[14]Descamps-Latscha B,Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure[J].Kidney Int,2001,59(78):S108-113.
[15]Capeillere-Blandin C,Gausson V, Descamps-Latscha B, et al.Biochemical and spectrophoto-metric significance of advanced oxidized protein products[J].Biochim Biophys Acta,2004,1689:91-102.
[16]Woods AA, Linton SM, Davies MJ. Detection of HOCL mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques[J].Biochem J,2003, 370(2):729-735.
[17]Peuchant E,Carbonneau MA.Dubourg L,et al. Lipoperoxidation in plasma and red blood cells of patients undergoing hemodialysis:Vitamin A,E and iron status[J].Free Radic Biol Med,1994,16(3):339-346.
[18]Miyata T, Taneda S,Kawai R, et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin forming amyloid fibrils in patients with dialysis-related amyloidosis[J].Proc Nalt Acad Sci USA,1996,93(6):2353-2358.
[19]Mcgrath LT, Douglas AF, McClean E, et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular HD[J].Clin Chim Acta,1995,235(2):179-188.
[20]Hassan MQ, Hussain SA, Zaki MA, et al.Prospective effects of antioxidants against uraemia-induced lipid peroxidation and glutathione depletion in humans[J].Pharmocol Toxicol,1995,77(6):407-411.
[21]Grone HJ, Grone EF, Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis[J].Lab Invest,2002,82(1): 5-14.
[22]Capeillere-Blandin C, Gausson V, Nguyen AT, et al.Respective role of uraemic toxins and myeloperoxidase in the uraemic state[J].Nephrol Dial Transplant,2006,21(6):1555-1563.
[23]Kalousova M, Zima T, Tesar Vet, et al. Advanced glycation end products and advanced Oxidation protein products in hemodialyzed patients[J].Blood Purify,2002,20(6): 531-536.
[24]Yuan F, Liu SX, Tian JW.Advanced oxidation protein products induce reactive oxygen species production in endothelial cells[J].Di Yi Jun Yi Da Xue Bao,2004,24(12): 1350-1352.
[25]Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Mail-lard reaction products in skin collagen in diabetes and aging[J].J Clin Invest,1993,91(6):2463-2469.
[26]Miyata T, Fu MX, Kurokawa K, et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma:Is there oxidative stress in uremia[J]?Kidney Int, 1998,54(4):1290-1295.
[27]Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease[J].Kidney Int,2000,57(6):2571-2585.
[28]Miyata T, Charles Van Ypersele de Strihou, Kurokawa K, et al. Alterations in non-enzymatic biochemistry in uremia:Origin and significance of "carbonyl stress"in long-term uremic complications [J].Kidney Int,1999,55:389-399.
[29]Miyata T, Ueda Y, Shizato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure:Renal implications in the pathophysiology of pentosidine[J].J Am Soc Nephrol,1996,7:1198- 1206.
[30]Miyata T, Ueda Y, Yoshida A, et al. Clearance of pentosidine, an advanced glycation end product,by different modalities of renal replacement therapy[J].Kidney Int,1997,51:880-887.
[31]Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure [J].Kidney Int, 1997,51(4):1170-1181.
[32]侯凡凡,张训,王斌会,等.Nε-羧甲基赖氨酸时慢性血液透析病人晚期糖基化终产物的天然结构[J].中华内科杂志,1998,37(10)：663-666.
[33]Fu M X,Requena J R,Jenkins AJ,et al. The advanced glycation end-product,Nε-(carboxymethyl) lysine (CML),is a product of both lipid peroxidation and glycation reactions[J].J Biol Chem,1996,271:9982-9986.
[34]Jan Galle.Oxidative stress in chronic renal failure[J].Nephrol Dial Transplant 2001,16: 2135-2137.
[35]Magus A, Mihkel z. Bengt E Endothelium-dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int.2003, (84):50-53.
[36]Diaz-Buxo JA,Gotloib L.Agents that modulate peritoneal mem-brane structure and function[J].Petit Dial Int,2007,27(1):16-30.
[37]Honda K,Nitta K,Horita S,et al.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure[J].Nephron,1996,72(2):171-176.
[38]Keshaviah P. Adequancy of peritoneal dialysis. In:Gokal R,Nolph KD.The texbook of peritoneal dialysis[M].Dordrecht:kluwer Academic publishers,1994:419-422.
[39]Herrera J,Nava M,Romero F,et al.Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis,2001 Apr:37(4):750-7
[40]Eiselt J,Racek J,Opatrny K Jr.Oxidative stress:the effect of erythropoietin and the dialysis membrane[J].Int J Artif Organs,2000,23(1):33-40
[41]Pawlaczyk K, Oko A, Lindholm B, et al.Malnutrition-inflammation-atherosclerosis (MIA syndrome) in patients with renal failure[J].Pol Merkuriusz Lek,2003,15(88):334-341.
[42]Decamps-Latscha B,Witko-Sarsat V, Nguyen-Khoa T, et al.Early prediction of IgA nephropathy progression:proteinuria and AOPP are strong prognostic makers[J].Kidney Int,2004,66(4):1606-161.
[43]Hou FF,Ma ZG,Mei CL,et al.Epidemiology of cardiovascular risk in Chinese chronic kidney disease patients[J].Chung-Hua I HSUCH Tsa Chih,2005,85(11):753-9.
[44]Robert N, Foley,Anne M, Murray, et al.Chronic Kidney Disease and the Risk for Cardiovascular Disease,Renal Replacement,and Death in the United States Medicare Population 1998 to 1999[J].J Am Soc Nephrol,2005,16(2):489-495.
[45]Alan S.Go,Glenn M.Chertow,Dongjie Fan,et al.Chronic Kidney Disease and the Risks of Death,Cardiovascular Events,and Hospitalization[J].N Engl J Med,2004,351(13): 1296-1305.
[46]Selmeci L,Antal M,et al.Advanced oxidation protein products(AOPP)for monitoring oxidative stress in critically ill patients:a simple,fast and inexpensive automated technique[J].Clin Chem Lab Med,2005,43(3):294-297.
[47]Stenvinkel P, Heimburger O, Paultre F, et al.Strong association between malnutritions inflammation,and atherosclerosis in chronic renal failure [J].Kidney Int,1999,55(5): 1899-1911
[48]Michael GS, Linda FF, Casey Crump, et al.Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency[J].Circulation,2003,107(1): 87-92
[49]齐志宏.C-反应蛋白与动脉粥样硬化的关系.北京医学,2005,27(4)：246-248.
[50]Kato A,Odamaik M,Taki,ta M,et al.C-reactive protein is a predictor of short-term mortality in hemodialysis patients[J].Am J Nephrol,2001,21(2):176-178
[51]Yeun JY, Levine RA, Mantadilok V, et al.C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis Patients[J].Am J Kidney Dis,2000,35(3): 469-476
[52]Cooper AC, Mikhail A, Lethbridge MW, et al.Increased expression of erythropoiesis inhibiting cytokines(IFN-7,TNF-a,IL-10 andlL-13)by T cells in patients exhibiting a poor response to erythropoietin therapy[J].J Am Soc Nephrol,2003,14(5):1776-1784.
[53]Pereira BJ, Shapiro L, King A J, et al.Plasma levels of IL-I beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure,CAPD and hemodialysis patients[J]. Kidney Int,1994,45(3):890-896
[54]Ortega O,Rodriquez I,Gallar P,et al.A.Significance of high C-reactive protein levels in pre-dialysis patients[J].Nephrol Dial Transplant,2002,17(6):1105-1109
[55]Boenisch O,EhmkeK D,Heddergott A,et al.C-reactive-protein and cytokine plasma levels in hemodialysis patients[J].J Nephrol,2002,5(5):547-551
[56]Raj DS, Lim G, Levi Metal.Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy[J].Am J Kidney Dis,2004,43(1):154-160
[57]Descamps Latscha B,Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis[J].Nephrologie,2003,24(7):377-379.
[58]Haubitz M, Brunkhorst R, Wrenger E, et al.Chronic induction of C-reactive protein by hemodialysis but not peritoneal dialysis therapy[J].Protein Dial Int.1996,16(2):158-162.
[59]Schindler R, Boenisch O, Fischer C, et al.Effects of hemodialysis membrane on the inflammatory reaction in vivo[J].Clin Nephrol.2000,53(6):452-459.
[60]Verthelyi D,Ishii KJ,Gursel M,et al.Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs[J].J Immunol,2001,166(4):2372-2377
[61]Elwakkad AS.Mohamed SI.Fathalla M.Relation between hypercholesterolemia and vascular endothelial microinflammation[J].Eastern Mediterranean Health Journal.2007, 13(3):191-199.
[62]Fichtlscherer S,Rosenberger G,Walter DH, et al.Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J].Circulation, 2000,102(9):1000-1006
[63]Verma S,Wang CH,Li SH,et al.A self-fulfilling prophecy:C-reactive protein attenustes nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106(8):913-919
[64]Cermak J, key NS, Bach RR, et al.C-reactive protein induces human peripheral blood monocytes to synthesize trssue factor[J].Blood,1993,82(2):513-520
[65]Libby P,Aikawa M.Stabilization of atherosclerotic plaques:new mechanisms and clinical targets[J].Nature Med,2002,8(11):1257-1262
[66]Stompor T, Pasowicz M, Sulowicz W,et al.An association between coronary artery calcificatronscore, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritioneal dialysis[J].Am J Kidney Dis,2003,41(1):203-211
[67]Kalantar-Zadeh K, McAllister CJ,Lehn RS,et al.Effect of malnutrition-Inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients[J]. Am J Kidney Dis,2003,42(4):761-773
[68]Tintut Y,Patel J,Parhami F,et al.Tumor necrosis factor-a promotes in vitro calcification of vascular cell via the cAMP pathway[J].Circulation,2000,102(5):2636-2842
[69]Baranyp, Divinho-Filho JC, Bergstrom J. Hight C-reactive protein in a strong predictor of resistance to erythropoietin in hemodialysis patients[J].Am J Kidney Dis,1997,29(3): 565-568
[70]Alleu DA,Breen C,Yaqoob MM,et al.Inhibition of CFU-E colony formation in nremic patients with inflammatory disease:role of 1FN-gamma and TNF-alpha[J].Investigative Med,1999,47(5):204-211
[71]Bovy C,Tsobo C,Crapanzano L, et al.Factors determining the percentage of hypochromic red blood cells in hemodialysis patients[J]. Kidney Int,1999,56(5):1113-1119
[72]Stenvinkel P, Heimburger O, Lindholm B,et al.Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition,inflammation and atherosclerosis(MIA)syndrome[J].Nephrol Dial Transplant,2000,15(7):953-960
[73]Hodkova M, Dusilova-Sulkova S,Skalicka A, et al.Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients[J].Ren Fail,2005,27(2):135-141
[74]Mune M, Yukawa S,Kishino M, et al.Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients[J].Kidney Int Suppl,1999,71:S126-129
[75]Tepel M, Van der Giet M, Statz M, et al.The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure:a randomized, controlled trial[J].Circulation,2003,107(7):992-995.
[76]Sezer MT, Katirci S, Demir M. Short-term effect of simvastain treatment on inflammatory parameters in peritoneal dialysis patients[J].Scandinavian journal of Urology & Nephrology, 2007,41(5):436-441.
[77]Kumar S,Raftery M, Yaqoob M, et al.Anti-inflammatory effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors(statins)in peritoneal dialysis patients[J]. Peritoneal Dialysis International,2007,27(3):283-287.
[78]何甲均,王煜伦,郑莘.ACEI与ATl受体拮抗剂合用治疗轻中度慢性肾衰高血压临床观察[J].天津医药,2004,32(2)：272--273